By virtue of the agreement announced on Monday, March 21 by both parties, the strategic alliance with Oncoclínicas, the leading oncology group in Brazil and Latin America, will allow MEDSIR to promote independent oncology research in Latin America and the United States, where it was already present.
Oncoclínicas, supported by its controlling shareholder Goldman Sachs, one of the largest and most prestigious investment banks in the world, becomes a 49% shareholder in MEDSIR to strengthen its international expansion.
In addition, this agreement reflects Oncoclínicas' global commitment to the fight against cancer and the support for independent research.
“This is a unique opportunity to promote independent cancer research. With this alliance, we can guide the strategies we offer to pharmaceutical companies based on a broader clinical and molecular data environment and carry out intelligent trials that allow us to work in a more comprehensive way and through a disruptive research model”, says María Campos, one of the co-founders and CEO of MEDSIR.
This strategic alliance allows MEDSIR to consolidate its international expansion, which began five years ago, as well as to lead one of the best global research networks in oncology. Incorporating the collaboration of more than 1.500 specialists, in addition to the access to Oncoclínicas genomics and diagnostic platform, MEDSIR will be able to create and design new intelligent trials based on the expertise of its leaders and involving artificial intelligence.
Dr. Javier Cortés, Maria Campos, Dr. Antonio Llombart-Cussac
Accordingly, Dr. Javier Cortés, medical oncologist and one of the co-founders of MEDSIR, has highlighted “there is a huge benefit to patients suffering from cancer to be able to rely on Oncoclínicas, with high quality international research as a result of the joining of forces between MEDSIR and Oncoclínicas, who could not be greater allies”.
From his side, Dr. Antonio Llombart, medical oncologist and one of the co-founders of MEDSIR, has insisted that "this transaction will further strengthen the capabilities of Oncoclínicas, by having the mentoring and scientific excellence of a leading company such as MEDSIR."
On the other hand, the new agreement represents an extension and improvement of Oncoclínicas’ current services portfolio (radiotherapy, personalized medicine, telemedicine and complementary treatments), by now adding to it the most innovative clinical and molecular research, as well as expanding its range of scientific collaborations, which includes the Dana-Farber Cancer Institute (Boston) and the Weizmann Institute of Science (Israel).
Our commitment to science and to our patients at the global level has never been stronger and we can’t be happier of this alliance to promote global research.
